All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2025-07-31.
From the record
Akso Health Group's filings since 2017 show 3 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2025-07-31) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+23.2% a year over 5 filed years; profitable in 0 of 5.
From the record
Akso Health Group's 5 filed years say what it did: revenue went from $6 million in fiscal 2022 to $14 million in fiscal 2026, up 23.2% a year; it rose in 2 of 4 years; the deepest fall was 82% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.1/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Akso Health Group's shareholder treatment is put at 5.1 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 80 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -10%: lost 10¢ per shareholder dollar. Leverage 5%: owes 5¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2026-03-31, Akso Health Group lost about 10 cents for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 0 cents per dollar of everything the company owns. Leverage: it owed about 5 cents per dollar of assets (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 17% of 101 in its family; net margin -135%.
From the record
Akso Health Group's standing among 101 graded names in its industry family: revenue of $14 million in fiscal 2026 ranks in the bottom 11% by size; a net margin of -135% ranks in the bottom 10%; revenue growth of 1.6% a year over the last 3 filed years ranks in the bottom 31% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.3/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Akso Health Group's leadership is put at 5.3 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 73 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 18% of 99 in its family for room to expand.
From the record
Akso Health Group's room to grow, from the newest filed statements (fiscal 2026): cash of $171 thousand against no long-term debt tagged leaves 0.1% of its assets as net cash, bottom 44% of its family; cash from operations less capital spending is -92.5% of revenue (bottom 8%); a gross margin of -0.1% (bottom 2%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 10% of 99 in its family for growth drivers.
From the record
Akso Health Group's growth drivers, from the filed years to fiscal 2026: revenue grew 1.6% a year over the last three filed years against 23.2% over all 5, slowing (bottom 12% of its family); the newest year grew -6.4% (bottom 18%); capital spending grew -98.9% a year (bottom 1%) (its annual reports). Akso Health Group tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 44% of 93 in its family for expectations against reality.
From the record
Akso Health Group's newest year against its own record: revenue of $14 million in fiscal 2026 came in 11.6% below the $16 million its prior three years' pace pointed to (bottom 17% of its family); net income of $19 million against a prior three-year average of $49 million (top 46%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 3%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made